Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and cryogenic biostorage within the life science industry. Its Life Sciences Products segment offers cryogenic freezers, cryogenic dewars, and accessories within the life science industry through direct sales or a distribution network. The company’s products include Cryoport Express Shippers; Cryoport ELITE Shippers; Cryoport Express Cryogenic HV3 Shipping System; Smartpak II Condition Monitoring System and Tec4Med; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as CRYOGENE, a biostorage solution for the provision of pre-clinical temperature-controlled biological materials management services; and Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; CRYOPDP, a temperature-controlled logistics solution; MVE Biological Solutions’ Fusion cryogenic system, a self-sustaining cryogenic freezer; and Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.
Cryoport's Crossroads | Explore Cryoport's strategic position in cold chain logistics, facing growth challenges amidst a declining stock price and market capitalization of $388 million |
Financial Headwinds | Delve into Cryoport's revised revenue guidance and cost-cutting measures, aiming for adjusted EBITDA profitability by 2025 despite recent downward trends |
Market Dynamics | Analyst targets range from $8 to $15 per share, reflecting mixed views on Cryoport's potential in the evolving cell and gene therapy secto |
Future Trajectory | Learn how new FDA approvals and cost reduction initiatives could reshape Cryoport's growth prospects, balancing against ongoing challenges in key segments |
Metrics to compare | CYRX | Sector Sector - Average of metrics from a broad group of related Industrials sector companies | Relationship RelationshipCYRXPeersSector | |
---|---|---|---|---|
P/E Ratio | −7.9x | −4.5x | −0.5x | |
PEG Ratio | −0.06 | 0.00 | 0.00 | |
Price/Book | 0.8x | 1.4x | 2.6x | |
Price / LTM Sales | 1.7x | 2.1x | 3.3x | |
Upside (Analyst Target) | 34.1% | 72.4% | 43.4% | |
Fair Value Upside | Unlock | 23.2% | 7.1% | Unlock |